double-stranded dna Search Results


91
Worthington Biochemical dnacellulose
Dnacellulose, supplied by Worthington Biochemical, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/double-stranded+dna/DNA+Cellulose%2C+Double-Stranded/10__1128_slash_jb__06003___11-81-36-37
Average 91 stars, based on 1 article reviews
dnacellulose - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

93
Cusabio 65901 mouse anti dsdna igg elisa kit
65901 Mouse Anti Dsdna Igg Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/double-stranded+dna/Mouse+anti-double+stranded+DNA+antibody+(IgG)+ELISA+Kit/pm38758648-183-140-146
Average 93 stars, based on 1 article reviews
65901 mouse anti dsdna igg elisa kit - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

98
Bio X Cell rat anti mouse cd16 32 clone 2 4g2
Rat Anti Mouse Cd16 32 Clone 2 4g2, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/double-stranded+dna/Anti-Dopamine+Receptor+D3+Rabbit+Monoclonal+Antibody/pm41742422-271-18-23
Average 98 stars, based on 1 article reviews
rat anti mouse cd16 32 clone 2 4g2 - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

94
TargetMol parp inhibitor olaparib
Figure 1. High-throughput screening shows that IDH1 inhibitor ivosidenib greatly sensitizes BRCA1/2-proficient cancer cells to PARPi. (A) The workflow for screening sensitizer drugs for the <t>PARP</t> inhibitor <t>Olaparib</t> in A2780 cells using an FDA-approved drug library (TargetMol, #L1000) that contains 2040 approved small molecule drugs. (B) The relative cell viability of A2780 cells grown in the presence of 10 µM of FDA-approved drugs alone (upper) or FDA-approved drugs plus 10 µM of Olaparib for 72 h; cell viability was analyzed through CCK-8 assay. (C) Ivosidenib increases Olaparib sensitivity in BRCA1/2-WT breast and ovarian cancer cells. Indicated cells were treated with increasing concentrations of Olaparib (ola) in the presence or absence of 5 µM of ivosidenib (Ivo) for 72 h, followed by cell viability analysis. (D) Ivosidenib and Olaparib synergistically suppress cancer cell growth. Indicated cells were co-treated with serial dosages of Olaparib and ivosidenib for 72 h, followed by Bliss synergy analysis. (E) Ivosidenib and Olaparib synergistically inhibit clonogenic survival in BRCA1/2-WT cancer cells. The colony formation analysis indicated cells treated with 2 µM of ivosidenib, 2 µM of Olaparib, or their combination. Data are presented as means ± SD, n = 6. * p < 0.05 and *** p < 0.001 based on the two-tailed t-test.
Parp Inhibitor Olaparib, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/double-stranded+dna/DNA+Damage+%26+Repair+Compound+Library/10__3390_slash_biomedicines13040958-83-24-35
Average 94 stars, based on 1 article reviews
parp inhibitor olaparib - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
Boster Bio mre11
Figure 1. High-throughput screening shows that IDH1 inhibitor ivosidenib greatly sensitizes BRCA1/2-proficient cancer cells to PARPi. (A) The workflow for screening sensitizer drugs for the <t>PARP</t> inhibitor <t>Olaparib</t> in A2780 cells using an FDA-approved drug library (TargetMol, #L1000) that contains 2040 approved small molecule drugs. (B) The relative cell viability of A2780 cells grown in the presence of 10 µM of FDA-approved drugs alone (upper) or FDA-approved drugs plus 10 µM of Olaparib for 72 h; cell viability was analyzed through CCK-8 assay. (C) Ivosidenib increases Olaparib sensitivity in BRCA1/2-WT breast and ovarian cancer cells. Indicated cells were treated with increasing concentrations of Olaparib (ola) in the presence or absence of 5 µM of ivosidenib (Ivo) for 72 h, followed by cell viability analysis. (D) Ivosidenib and Olaparib synergistically suppress cancer cell growth. Indicated cells were co-treated with serial dosages of Olaparib and ivosidenib for 72 h, followed by Bliss synergy analysis. (E) Ivosidenib and Olaparib synergistically inhibit clonogenic survival in BRCA1/2-WT cancer cells. The colony formation analysis indicated cells treated with 2 µM of ivosidenib, 2 µM of Olaparib, or their combination. Data are presented as means ± SD, n = 6. * p < 0.05 and *** p < 0.001 based on the two-tailed t-test.
Mre11, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/double-stranded+dna/Anti-Mre11+Antibody/pm41486457-247-54-55
Average 90 stars, based on 1 article reviews
mre11 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
Cusabio sku dsd31 k01
Figure 1. High-throughput screening shows that IDH1 inhibitor ivosidenib greatly sensitizes BRCA1/2-proficient cancer cells to PARPi. (A) The workflow for screening sensitizer drugs for the <t>PARP</t> inhibitor <t>Olaparib</t> in A2780 cells using an FDA-approved drug library (TargetMol, #L1000) that contains 2040 approved small molecule drugs. (B) The relative cell viability of A2780 cells grown in the presence of 10 µM of FDA-approved drugs alone (upper) or FDA-approved drugs plus 10 µM of Olaparib for 72 h; cell viability was analyzed through CCK-8 assay. (C) Ivosidenib increases Olaparib sensitivity in BRCA1/2-WT breast and ovarian cancer cells. Indicated cells were treated with increasing concentrations of Olaparib (ola) in the presence or absence of 5 µM of ivosidenib (Ivo) for 72 h, followed by cell viability analysis. (D) Ivosidenib and Olaparib synergistically suppress cancer cell growth. Indicated cells were co-treated with serial dosages of Olaparib and ivosidenib for 72 h, followed by Bliss synergy analysis. (E) Ivosidenib and Olaparib synergistically inhibit clonogenic survival in BRCA1/2-WT cancer cells. The colony formation analysis indicated cells treated with 2 µM of ivosidenib, 2 µM of Olaparib, or their combination. Data are presented as means ± SD, n = 6. * p < 0.05 and *** p < 0.001 based on the two-tailed t-test.
Sku Dsd31 K01, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/double-stranded+dna/Human+anti-double+stranded+DNA(dsDNA)+antibody(IgG)+ELISA+Kit/pm37062567-116-74-76
Average 93 stars, based on 1 article reviews
sku dsd31 k01 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Cusabio mouse anti dsdna elisa kit
Figure 1. High-throughput screening shows that IDH1 inhibitor ivosidenib greatly sensitizes BRCA1/2-proficient cancer cells to PARPi. (A) The workflow for screening sensitizer drugs for the <t>PARP</t> inhibitor <t>Olaparib</t> in A2780 cells using an FDA-approved drug library (TargetMol, #L1000) that contains 2040 approved small molecule drugs. (B) The relative cell viability of A2780 cells grown in the presence of 10 µM of FDA-approved drugs alone (upper) or FDA-approved drugs plus 10 µM of Olaparib for 72 h; cell viability was analyzed through CCK-8 assay. (C) Ivosidenib increases Olaparib sensitivity in BRCA1/2-WT breast and ovarian cancer cells. Indicated cells were treated with increasing concentrations of Olaparib (ola) in the presence or absence of 5 µM of ivosidenib (Ivo) for 72 h, followed by cell viability analysis. (D) Ivosidenib and Olaparib synergistically suppress cancer cell growth. Indicated cells were co-treated with serial dosages of Olaparib and ivosidenib for 72 h, followed by Bliss synergy analysis. (E) Ivosidenib and Olaparib synergistically inhibit clonogenic survival in BRCA1/2-WT cancer cells. The colony formation analysis indicated cells treated with 2 µM of ivosidenib, 2 µM of Olaparib, or their combination. Data are presented as means ± SD, n = 6. * p < 0.05 and *** p < 0.001 based on the two-tailed t-test.
Mouse Anti Dsdna Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/double-stranded+dna/Mouse+anti-double+stranded+DNA+antibody(IgM)ELISA+Kit/pmc08553505-80-7-11
Average 93 stars, based on 1 article reviews
mouse anti dsdna elisa kit - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Boster Bio anti dsba antibody
Figure 1. High-throughput screening shows that IDH1 inhibitor ivosidenib greatly sensitizes BRCA1/2-proficient cancer cells to PARPi. (A) The workflow for screening sensitizer drugs for the <t>PARP</t> inhibitor <t>Olaparib</t> in A2780 cells using an FDA-approved drug library (TargetMol, #L1000) that contains 2040 approved small molecule drugs. (B) The relative cell viability of A2780 cells grown in the presence of 10 µM of FDA-approved drugs alone (upper) or FDA-approved drugs plus 10 µM of Olaparib for 72 h; cell viability was analyzed through CCK-8 assay. (C) Ivosidenib increases Olaparib sensitivity in BRCA1/2-WT breast and ovarian cancer cells. Indicated cells were treated with increasing concentrations of Olaparib (ola) in the presence or absence of 5 µM of ivosidenib (Ivo) for 72 h, followed by cell viability analysis. (D) Ivosidenib and Olaparib synergistically suppress cancer cell growth. Indicated cells were co-treated with serial dosages of Olaparib and ivosidenib for 72 h, followed by Bliss synergy analysis. (E) Ivosidenib and Olaparib synergistically inhibit clonogenic survival in BRCA1/2-WT cancer cells. The colony formation analysis indicated cells treated with 2 µM of ivosidenib, 2 µM of Olaparib, or their combination. Data are presented as means ± SD, n = 6. * p < 0.05 and *** p < 0.001 based on the two-tailed t-test.
Anti Dsba Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/double-stranded+dna/Human+Disulfide+oxidoreductase%2FDsbA+Recombinant+Protein/pmc12398576__42003_2025_8749_MOESM1_ESM-213-38-40
Average 93 stars, based on 1 article reviews
anti dsba antibody - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
TargetMol beas 2b human lung epithelia cells
Figure 1. High-throughput screening shows that IDH1 inhibitor ivosidenib greatly sensitizes BRCA1/2-proficient cancer cells to PARPi. (A) The workflow for screening sensitizer drugs for the <t>PARP</t> inhibitor <t>Olaparib</t> in A2780 cells using an FDA-approved drug library (TargetMol, #L1000) that contains 2040 approved small molecule drugs. (B) The relative cell viability of A2780 cells grown in the presence of 10 µM of FDA-approved drugs alone (upper) or FDA-approved drugs plus 10 µM of Olaparib for 72 h; cell viability was analyzed through CCK-8 assay. (C) Ivosidenib increases Olaparib sensitivity in BRCA1/2-WT breast and ovarian cancer cells. Indicated cells were treated with increasing concentrations of Olaparib (ola) in the presence or absence of 5 µM of ivosidenib (Ivo) for 72 h, followed by cell viability analysis. (D) Ivosidenib and Olaparib synergistically suppress cancer cell growth. Indicated cells were co-treated with serial dosages of Olaparib and ivosidenib for 72 h, followed by Bliss synergy analysis. (E) Ivosidenib and Olaparib synergistically inhibit clonogenic survival in BRCA1/2-WT cancer cells. The colony formation analysis indicated cells treated with 2 µM of ivosidenib, 2 µM of Olaparib, or their combination. Data are presented as means ± SD, n = 6. * p < 0.05 and *** p < 0.001 based on the two-tailed t-test.
Beas 2b Human Lung Epithelia Cells, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/double-stranded+dna/XRCC5+Protein%2C+Human%2C+Recombinant/pm41285311-177-0-31
Average 93 stars, based on 1 article reviews
beas 2b human lung epithelia cells - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

92
Boster Bio antibodies to ku80 pb9464
Fig. 5. Quercetin inhibited NHEJ and HR pathways phosphorylation. Total proteins lysis and extraction after A549 and H1299 cultured with 0, 12.5, 50, and 200 μM quercetin for 24 h. In NHEJ pathways (A) the expression of p-DNA-PKcsS2056 (B, C), KU70 (D, E) and <t>KU80</t> (F, G), and in HR pathways (H) the phosphorylation of p- ATRS428 (I, J), p-Chek1S345 (K, L), p-ATMS1981 (M, N) and Chek2T68 (O, P) were detected by western blot in both A549 and H1299 cells. And the results were measured by ImageJ and expressed as protein expression relative to GAPDH (mean ± S.D., n = 3). #p > 0.05, *p < 0.05, * *p < 0.01, * **p < 0.001 relative to values in the respective 0 μM group (B, p = 0.0048, R2 =0.7844, F=9.700; C, p = 0.0002, R2 =0.9042, F=25.17; D, p = 0.0054, R2 =0.7782, F=9.358; E, p = 0.0045, R2 =0.7879, F=9.908; F, p = 0.0037, R2 =0.7990, F=10.60; G, p = 0.0016, R2 =0.8379, F=13.79; I, p = 0.0034, R2 =0.8028, F=10.85; J, p = 0.0032, R2 =0.8066, F=11.12; K, p = 0.0010, R2 =0.8564, F=15.91; L, p = 0.0016, R2 =0.8379, F=13.79; M, p = 0.0044, R2 =0.7898, F=10.02; N, p = 0.0065, R2 =0.7676, F=8.806; O, p = 0.0030, R2 =0.0.8087, F=11.27; P, p = 0.0026, R2 =0.8166, F=11.87), One-way ANOVA test. The mRNA in A549 (Q) and H1299 (R) cells was extracted and reverse transcribed to cDNA for RT-qPCR analysis (mean ± S.D., n = 3). #p > 0.05, *p < 0.05, * *p < 0.01, * **p < 0.001, * ** *p < 0.0001 relative to values in the respective 0 μM group, One-way ANOVA test.
Antibodies To Ku80 Pb9464, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/double-stranded+dna/Anti-Ku80%2FXRCC5+Antibody+Picoband/pm37390710-118-29-38
Average 92 stars, based on 1 article reviews
antibodies to ku80 pb9464 - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

90
Boster Bio monoclonal antibody
Fig. 5. Quercetin inhibited NHEJ and HR pathways phosphorylation. Total proteins lysis and extraction after A549 and H1299 cultured with 0, 12.5, 50, and 200 μM quercetin for 24 h. In NHEJ pathways (A) the expression of p-DNA-PKcsS2056 (B, C), KU70 (D, E) and <t>KU80</t> (F, G), and in HR pathways (H) the phosphorylation of p- ATRS428 (I, J), p-Chek1S345 (K, L), p-ATMS1981 (M, N) and Chek2T68 (O, P) were detected by western blot in both A549 and H1299 cells. And the results were measured by ImageJ and expressed as protein expression relative to GAPDH (mean ± S.D., n = 3). #p > 0.05, *p < 0.05, * *p < 0.01, * **p < 0.001 relative to values in the respective 0 μM group (B, p = 0.0048, R2 =0.7844, F=9.700; C, p = 0.0002, R2 =0.9042, F=25.17; D, p = 0.0054, R2 =0.7782, F=9.358; E, p = 0.0045, R2 =0.7879, F=9.908; F, p = 0.0037, R2 =0.7990, F=10.60; G, p = 0.0016, R2 =0.8379, F=13.79; I, p = 0.0034, R2 =0.8028, F=10.85; J, p = 0.0032, R2 =0.8066, F=11.12; K, p = 0.0010, R2 =0.8564, F=15.91; L, p = 0.0016, R2 =0.8379, F=13.79; M, p = 0.0044, R2 =0.7898, F=10.02; N, p = 0.0065, R2 =0.7676, F=8.806; O, p = 0.0030, R2 =0.0.8087, F=11.27; P, p = 0.0026, R2 =0.8166, F=11.87), One-way ANOVA test. The mRNA in A549 (Q) and H1299 (R) cells was extracted and reverse transcribed to cDNA for RT-qPCR analysis (mean ± S.D., n = 3). #p > 0.05, *p < 0.05, * *p < 0.01, * **p < 0.001, * ** *p < 0.0001 relative to values in the respective 0 μM group, One-way ANOVA test.
Monoclonal Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/double-stranded+dna/Anti-Ku-80+XRCC5+Monoclonal+Antibody/pmc03406497-44-18-20
Average 90 stars, based on 1 article reviews
monoclonal antibody - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
Boster Bio anti rabbit secondary antibody
Fig. 5. Quercetin inhibited NHEJ and HR pathways phosphorylation. Total proteins lysis and extraction after A549 and H1299 cultured with 0, 12.5, 50, and 200 μM quercetin for 24 h. In NHEJ pathways (A) the expression of p-DNA-PKcsS2056 (B, C), KU70 (D, E) and <t>KU80</t> (F, G), and in HR pathways (H) the phosphorylation of p- ATRS428 (I, J), p-Chek1S345 (K, L), p-ATMS1981 (M, N) and Chek2T68 (O, P) were detected by western blot in both A549 and H1299 cells. And the results were measured by ImageJ and expressed as protein expression relative to GAPDH (mean ± S.D., n = 3). #p > 0.05, *p < 0.05, * *p < 0.01, * **p < 0.001 relative to values in the respective 0 μM group (B, p = 0.0048, R2 =0.7844, F=9.700; C, p = 0.0002, R2 =0.9042, F=25.17; D, p = 0.0054, R2 =0.7782, F=9.358; E, p = 0.0045, R2 =0.7879, F=9.908; F, p = 0.0037, R2 =0.7990, F=10.60; G, p = 0.0016, R2 =0.8379, F=13.79; I, p = 0.0034, R2 =0.8028, F=10.85; J, p = 0.0032, R2 =0.8066, F=11.12; K, p = 0.0010, R2 =0.8564, F=15.91; L, p = 0.0016, R2 =0.8379, F=13.79; M, p = 0.0044, R2 =0.7898, F=10.02; N, p = 0.0065, R2 =0.7676, F=8.806; O, p = 0.0030, R2 =0.0.8087, F=11.27; P, p = 0.0026, R2 =0.8166, F=11.87), One-way ANOVA test. The mRNA in A549 (Q) and H1299 (R) cells was extracted and reverse transcribed to cDNA for RT-qPCR analysis (mean ± S.D., n = 3). #p > 0.05, *p < 0.05, * *p < 0.01, * **p < 0.001, * ** *p < 0.0001 relative to values in the respective 0 μM group, One-way ANOVA test.
Anti Rabbit Secondary Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/double-stranded+dna/Anti-Ku80+XRCC5+Rabbit+Monoclonal+Antibody/pm24604116-39-8-12
Average 93 stars, based on 1 article reviews
anti rabbit secondary antibody - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


Figure 1. High-throughput screening shows that IDH1 inhibitor ivosidenib greatly sensitizes BRCA1/2-proficient cancer cells to PARPi. (A) The workflow for screening sensitizer drugs for the PARP inhibitor Olaparib in A2780 cells using an FDA-approved drug library (TargetMol, #L1000) that contains 2040 approved small molecule drugs. (B) The relative cell viability of A2780 cells grown in the presence of 10 µM of FDA-approved drugs alone (upper) or FDA-approved drugs plus 10 µM of Olaparib for 72 h; cell viability was analyzed through CCK-8 assay. (C) Ivosidenib increases Olaparib sensitivity in BRCA1/2-WT breast and ovarian cancer cells. Indicated cells were treated with increasing concentrations of Olaparib (ola) in the presence or absence of 5 µM of ivosidenib (Ivo) for 72 h, followed by cell viability analysis. (D) Ivosidenib and Olaparib synergistically suppress cancer cell growth. Indicated cells were co-treated with serial dosages of Olaparib and ivosidenib for 72 h, followed by Bliss synergy analysis. (E) Ivosidenib and Olaparib synergistically inhibit clonogenic survival in BRCA1/2-WT cancer cells. The colony formation analysis indicated cells treated with 2 µM of ivosidenib, 2 µM of Olaparib, or their combination. Data are presented as means ± SD, n = 6. * p < 0.05 and *** p < 0.001 based on the two-tailed t-test.

Journal: Biomedicines

Article Title: Ivosidenib Confers BRCAness Phenotype and Synthetic Lethality to Poly (ADP-Ribose) Polymerase Inhibition in BRCA1/2-Proficient Cancer Cells

doi: 10.3390/biomedicines13040958

Figure Lengend Snippet: Figure 1. High-throughput screening shows that IDH1 inhibitor ivosidenib greatly sensitizes BRCA1/2-proficient cancer cells to PARPi. (A) The workflow for screening sensitizer drugs for the PARP inhibitor Olaparib in A2780 cells using an FDA-approved drug library (TargetMol, #L1000) that contains 2040 approved small molecule drugs. (B) The relative cell viability of A2780 cells grown in the presence of 10 µM of FDA-approved drugs alone (upper) or FDA-approved drugs plus 10 µM of Olaparib for 72 h; cell viability was analyzed through CCK-8 assay. (C) Ivosidenib increases Olaparib sensitivity in BRCA1/2-WT breast and ovarian cancer cells. Indicated cells were treated with increasing concentrations of Olaparib (ola) in the presence or absence of 5 µM of ivosidenib (Ivo) for 72 h, followed by cell viability analysis. (D) Ivosidenib and Olaparib synergistically suppress cancer cell growth. Indicated cells were co-treated with serial dosages of Olaparib and ivosidenib for 72 h, followed by Bliss synergy analysis. (E) Ivosidenib and Olaparib synergistically inhibit clonogenic survival in BRCA1/2-WT cancer cells. The colony formation analysis indicated cells treated with 2 µM of ivosidenib, 2 µM of Olaparib, or their combination. Data are presented as means ± SD, n = 6. * p < 0.05 and *** p < 0.001 based on the two-tailed t-test.

Article Snippet: High-throughput screening shows that IDH1 inhibi r ivosidenib greatly sensitizes BRCA1/2-proficient cancer cells to PARPi. (A) The workflow for screening sensitizer drugs for the PARP inhibitor Olaparib in A2780 cells using an FDA-approved drug library (TargetMol, #L1000) that contains 2040 approved small molecule drugs. (B) The relative cell viability of A2780 cells grown in the presence of 10 μM of FDA-app oved drugs alone (upper) o FDA-approved drugs plus 10 μM of Olaparib for 72 h; cell viability was analyzed through CCK-8 assay. (C) Ivosidenib increases Olaparib sensitivity in BRCA1/2-WT breast and ovarian cancer cells.

Techniques: High Throughput Screening Assay, Drug discovery, CCK-8 Assay, Two Tailed Test

Figure 2. Ivosidenib (Ivo) greatly potentiates Olaparib (Ola)-induced DNA damage in BRCA1/2- proficient cells. (A) Ivosidenib enhances Olaparib-induced γH2AX formation in BRCA1/2-WT cancer cells. Indicated cells were treated with 50 µM of Ola, 10 µM of Ivo, or their combination for 48 h, followed by Western blot analysis of γH2AX. (B) Ivosidenib delayed the reduction of γH2AX after Olaparib treatment. A2780 cells were treated with 100 µM for 48 h and then released into normal culture medium in the presence or absence of Ivo for indicated time points, followed by Western blot analysis of γH2AX. (C) Ivosidenib increases Olaparib-caused DNA damage. A2780 cells were treated with 50 µM of Ola, 10 µM of Ivo, or their combination for 48 h, followed by measuring the DNA damage through comet assay. Data are presented as means ± SD.

Journal: Biomedicines

Article Title: Ivosidenib Confers BRCAness Phenotype and Synthetic Lethality to Poly (ADP-Ribose) Polymerase Inhibition in BRCA1/2-Proficient Cancer Cells

doi: 10.3390/biomedicines13040958

Figure Lengend Snippet: Figure 2. Ivosidenib (Ivo) greatly potentiates Olaparib (Ola)-induced DNA damage in BRCA1/2- proficient cells. (A) Ivosidenib enhances Olaparib-induced γH2AX formation in BRCA1/2-WT cancer cells. Indicated cells were treated with 50 µM of Ola, 10 µM of Ivo, or their combination for 48 h, followed by Western blot analysis of γH2AX. (B) Ivosidenib delayed the reduction of γH2AX after Olaparib treatment. A2780 cells were treated with 100 µM for 48 h and then released into normal culture medium in the presence or absence of Ivo for indicated time points, followed by Western blot analysis of γH2AX. (C) Ivosidenib increases Olaparib-caused DNA damage. A2780 cells were treated with 50 µM of Ola, 10 µM of Ivo, or their combination for 48 h, followed by measuring the DNA damage through comet assay. Data are presented as means ± SD.

Article Snippet: High-throughput screening shows that IDH1 inhibi r ivosidenib greatly sensitizes BRCA1/2-proficient cancer cells to PARPi. (A) The workflow for screening sensitizer drugs for the PARP inhibitor Olaparib in A2780 cells using an FDA-approved drug library (TargetMol, #L1000) that contains 2040 approved small molecule drugs. (B) The relative cell viability of A2780 cells grown in the presence of 10 μM of FDA-app oved drugs alone (upper) o FDA-approved drugs plus 10 μM of Olaparib for 72 h; cell viability was analyzed through CCK-8 assay. (C) Ivosidenib increases Olaparib sensitivity in BRCA1/2-WT breast and ovarian cancer cells.

Techniques: Western Blot, Single Cell Gel Electrophoresis

Figure 3. Ivosidenib (Ivo) treatment suppresses the repair of Olaparib (Ola)-induced DSBs. Ivosidenib inhibits HR repair. (A,B) Ivosidenib A2780 cells were treated with 50 of µM Ola, 10 µM of Ivo, or their combination for 48 h, followed by immunofluorescence analysis of Rad51/γH2AX (A) or RPA2/γH2AX (B). (C) Cells were treated as indicated for 48 h, followed by Western blot analysis of pRPA2 S4/8. Data were are presented as means ± SD. ** p < 0.01 and *** p < 0.001 according to the two2-tailed t-test.

Journal: Biomedicines

Article Title: Ivosidenib Confers BRCAness Phenotype and Synthetic Lethality to Poly (ADP-Ribose) Polymerase Inhibition in BRCA1/2-Proficient Cancer Cells

doi: 10.3390/biomedicines13040958

Figure Lengend Snippet: Figure 3. Ivosidenib (Ivo) treatment suppresses the repair of Olaparib (Ola)-induced DSBs. Ivosidenib inhibits HR repair. (A,B) Ivosidenib A2780 cells were treated with 50 of µM Ola, 10 µM of Ivo, or their combination for 48 h, followed by immunofluorescence analysis of Rad51/γH2AX (A) or RPA2/γH2AX (B). (C) Cells were treated as indicated for 48 h, followed by Western blot analysis of pRPA2 S4/8. Data were are presented as means ± SD. ** p < 0.01 and *** p < 0.001 according to the two2-tailed t-test.

Article Snippet: High-throughput screening shows that IDH1 inhibi r ivosidenib greatly sensitizes BRCA1/2-proficient cancer cells to PARPi. (A) The workflow for screening sensitizer drugs for the PARP inhibitor Olaparib in A2780 cells using an FDA-approved drug library (TargetMol, #L1000) that contains 2040 approved small molecule drugs. (B) The relative cell viability of A2780 cells grown in the presence of 10 μM of FDA-app oved drugs alone (upper) o FDA-approved drugs plus 10 μM of Olaparib for 72 h; cell viability was analyzed through CCK-8 assay. (C) Ivosidenib increases Olaparib sensitivity in BRCA1/2-WT breast and ovarian cancer cells.

Techniques: Immunofluorescence, Western Blot

Figure 5. YTHDC2 knockdown suppresses HR repair. (A) Schematic diagram of HR repair reporter system (DR-GFP). (B,C) Silencing of YTHDC2 decreases HR repair. QU20S-DRGFP cells were transfected with control (ctrl) or YTHDC2 siRNA and, 24 h later, cells were transfected with pCBASceI plasmid to induce endonuclease-induced DSB, followed by flow cytometry analysis of GFP expression 48 h after pCBASceI expression (B). A2780 cells were transfected with control (Ctrl) or YTHDC2 siRNA; cells were then treated with 50 µM of Olaparib for 48 h, followed by immunofluorescence analysis of Rad51/γH2AX (C). Data are presented as means ± SD. *** p < 0.001 according to the two-tailed t-test.

Journal: Biomedicines

Article Title: Ivosidenib Confers BRCAness Phenotype and Synthetic Lethality to Poly (ADP-Ribose) Polymerase Inhibition in BRCA1/2-Proficient Cancer Cells

doi: 10.3390/biomedicines13040958

Figure Lengend Snippet: Figure 5. YTHDC2 knockdown suppresses HR repair. (A) Schematic diagram of HR repair reporter system (DR-GFP). (B,C) Silencing of YTHDC2 decreases HR repair. QU20S-DRGFP cells were transfected with control (ctrl) or YTHDC2 siRNA and, 24 h later, cells were transfected with pCBASceI plasmid to induce endonuclease-induced DSB, followed by flow cytometry analysis of GFP expression 48 h after pCBASceI expression (B). A2780 cells were transfected with control (Ctrl) or YTHDC2 siRNA; cells were then treated with 50 µM of Olaparib for 48 h, followed by immunofluorescence analysis of Rad51/γH2AX (C). Data are presented as means ± SD. *** p < 0.001 according to the two-tailed t-test.

Article Snippet: High-throughput screening shows that IDH1 inhibi r ivosidenib greatly sensitizes BRCA1/2-proficient cancer cells to PARPi. (A) The workflow for screening sensitizer drugs for the PARP inhibitor Olaparib in A2780 cells using an FDA-approved drug library (TargetMol, #L1000) that contains 2040 approved small molecule drugs. (B) The relative cell viability of A2780 cells grown in the presence of 10 μM of FDA-app oved drugs alone (upper) o FDA-approved drugs plus 10 μM of Olaparib for 72 h; cell viability was analyzed through CCK-8 assay. (C) Ivosidenib increases Olaparib sensitivity in BRCA1/2-WT breast and ovarian cancer cells.

Techniques: Knockdown, Transfection, Control, Plasmid Preparation, Flow Cytometry, Expressing, Immunofluorescence, Two Tailed Test

Figure 7. Combination treatment of ivosidenib (Ivo) and Olaparib (Ola) produces synergistic anti- tumor efficacy in BRCA1/2-proficient ovarian cancers. (A–C) Ivosidenib and Olaparib synergistically suppress tumor growth. A2780 xenograft bearing mice treated with Ola (100 mg/kg, orally) and Ivo (100 mg/kg, orally) and tumor growth curve (A), tumor image (B), and tumor weights (C) are shown. (D,E) Co-treatment with ivosidenib and Olaparib greatly induces DSBs and reduces proliferation in A2780 xenograft tumors. Immunohistochemistry analysis of γH2AX (D) and Ki67 (E) in tumors treated as indicated. Data are presented as means ± SD. *** p < 0.001 according to the two-tailed t-test.

Journal: Biomedicines

Article Title: Ivosidenib Confers BRCAness Phenotype and Synthetic Lethality to Poly (ADP-Ribose) Polymerase Inhibition in BRCA1/2-Proficient Cancer Cells

doi: 10.3390/biomedicines13040958

Figure Lengend Snippet: Figure 7. Combination treatment of ivosidenib (Ivo) and Olaparib (Ola) produces synergistic anti- tumor efficacy in BRCA1/2-proficient ovarian cancers. (A–C) Ivosidenib and Olaparib synergistically suppress tumor growth. A2780 xenograft bearing mice treated with Ola (100 mg/kg, orally) and Ivo (100 mg/kg, orally) and tumor growth curve (A), tumor image (B), and tumor weights (C) are shown. (D,E) Co-treatment with ivosidenib and Olaparib greatly induces DSBs and reduces proliferation in A2780 xenograft tumors. Immunohistochemistry analysis of γH2AX (D) and Ki67 (E) in tumors treated as indicated. Data are presented as means ± SD. *** p < 0.001 according to the two-tailed t-test.

Article Snippet: High-throughput screening shows that IDH1 inhibi r ivosidenib greatly sensitizes BRCA1/2-proficient cancer cells to PARPi. (A) The workflow for screening sensitizer drugs for the PARP inhibitor Olaparib in A2780 cells using an FDA-approved drug library (TargetMol, #L1000) that contains 2040 approved small molecule drugs. (B) The relative cell viability of A2780 cells grown in the presence of 10 μM of FDA-app oved drugs alone (upper) o FDA-approved drugs plus 10 μM of Olaparib for 72 h; cell viability was analyzed through CCK-8 assay. (C) Ivosidenib increases Olaparib sensitivity in BRCA1/2-WT breast and ovarian cancer cells.

Techniques: Immunohistochemistry, Two Tailed Test

Fig. 5. Quercetin inhibited NHEJ and HR pathways phosphorylation. Total proteins lysis and extraction after A549 and H1299 cultured with 0, 12.5, 50, and 200 μM quercetin for 24 h. In NHEJ pathways (A) the expression of p-DNA-PKcsS2056 (B, C), KU70 (D, E) and KU80 (F, G), and in HR pathways (H) the phosphorylation of p- ATRS428 (I, J), p-Chek1S345 (K, L), p-ATMS1981 (M, N) and Chek2T68 (O, P) were detected by western blot in both A549 and H1299 cells. And the results were measured by ImageJ and expressed as protein expression relative to GAPDH (mean ± S.D., n = 3). #p > 0.05, *p < 0.05, * *p < 0.01, * **p < 0.001 relative to values in the respective 0 μM group (B, p = 0.0048, R2 =0.7844, F=9.700; C, p = 0.0002, R2 =0.9042, F=25.17; D, p = 0.0054, R2 =0.7782, F=9.358; E, p = 0.0045, R2 =0.7879, F=9.908; F, p = 0.0037, R2 =0.7990, F=10.60; G, p = 0.0016, R2 =0.8379, F=13.79; I, p = 0.0034, R2 =0.8028, F=10.85; J, p = 0.0032, R2 =0.8066, F=11.12; K, p = 0.0010, R2 =0.8564, F=15.91; L, p = 0.0016, R2 =0.8379, F=13.79; M, p = 0.0044, R2 =0.7898, F=10.02; N, p = 0.0065, R2 =0.7676, F=8.806; O, p = 0.0030, R2 =0.0.8087, F=11.27; P, p = 0.0026, R2 =0.8166, F=11.87), One-way ANOVA test. The mRNA in A549 (Q) and H1299 (R) cells was extracted and reverse transcribed to cDNA for RT-qPCR analysis (mean ± S.D., n = 3). #p > 0.05, *p < 0.05, * *p < 0.01, * **p < 0.001, * ** *p < 0.0001 relative to values in the respective 0 μM group, One-way ANOVA test.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Quercetin inhibits DNA damage responses to induce apoptosis via SIRT5/PI3K/AKT pathway in non-small cell lung cancer.

doi: 10.1016/j.biopha.2023.115071

Figure Lengend Snippet: Fig. 5. Quercetin inhibited NHEJ and HR pathways phosphorylation. Total proteins lysis and extraction after A549 and H1299 cultured with 0, 12.5, 50, and 200 μM quercetin for 24 h. In NHEJ pathways (A) the expression of p-DNA-PKcsS2056 (B, C), KU70 (D, E) and KU80 (F, G), and in HR pathways (H) the phosphorylation of p- ATRS428 (I, J), p-Chek1S345 (K, L), p-ATMS1981 (M, N) and Chek2T68 (O, P) were detected by western blot in both A549 and H1299 cells. And the results were measured by ImageJ and expressed as protein expression relative to GAPDH (mean ± S.D., n = 3). #p > 0.05, *p < 0.05, * *p < 0.01, * **p < 0.001 relative to values in the respective 0 μM group (B, p = 0.0048, R2 =0.7844, F=9.700; C, p = 0.0002, R2 =0.9042, F=25.17; D, p = 0.0054, R2 =0.7782, F=9.358; E, p = 0.0045, R2 =0.7879, F=9.908; F, p = 0.0037, R2 =0.7990, F=10.60; G, p = 0.0016, R2 =0.8379, F=13.79; I, p = 0.0034, R2 =0.8028, F=10.85; J, p = 0.0032, R2 =0.8066, F=11.12; K, p = 0.0010, R2 =0.8564, F=15.91; L, p = 0.0016, R2 =0.8379, F=13.79; M, p = 0.0044, R2 =0.7898, F=10.02; N, p = 0.0065, R2 =0.7676, F=8.806; O, p = 0.0030, R2 =0.0.8087, F=11.27; P, p = 0.0026, R2 =0.8166, F=11.87), One-way ANOVA test. The mRNA in A549 (Q) and H1299 (R) cells was extracted and reverse transcribed to cDNA for RT-qPCR analysis (mean ± S.D., n = 3). #p > 0.05, *p < 0.05, * *p < 0.01, * **p < 0.001, * ** *p < 0.0001 relative to values in the respective 0 μM group, One-way ANOVA test.

Article Snippet: Antibodies to γ-H2AXS139, p-ATRS428 (AP0676) and p-CDK1T161 (AP0324) were from Abclonal Technology (Abclonal, Wuhan, China); antibodies to KU70 (AF0300) and p-Chek1Ser345 (AF3008) were from Affinity Biosciences (Affinity, Jiangsu, China); antibodies to KU80 (PB9464) and p-DNAPKcsS2056 (BM4058) were from Boster Biological Technology (Boster, Wuhan, China); antibodies to p-ATMSER1981 (bsm-54103R) and pChek2Thr68 (ba-3721R) were from Biosynthesis Biotechnology (Bioss, Beijing, China); antibodies to p-PI3K (17366) and p-AKT (4060) were from Cell Signaling Technology (Danvers, MA, USA); antibodies to Caspase-3 (ab32042), Bax (ab32503), Bcl-2 (ab32124), SIRT5 (ab259967), GAPDH (ab9485) and β-tubulin (ab179511) were from Abcam (Abcam, Cambridge, UK).

Techniques: Phospho-proteomics, Lysis, Extraction, Cell Culture, Expressing, Western Blot, Reverse Transcription, Quantitative RT-PCR